PsyBio continues to innovate, develop and
optimize technology related to its ever growing
psycho-targeted portfolio
OXFORD, Ohio and COCONUT CREEK, Fla., Dec. 2, 2021 /CNW/ - PsyBio Therapeutics
Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the
"Company"), an intellectual property driven biotechnology
company focused on discovery and development of novel,
bespoke, psycho-targeted therapeutics to potentially
improve mental and neurological health, today announced, as a
result of its sponsored research agreements, sixteen abstracts were
submitted for review, accepted through a peer-reviewed process and
presented at two scientific conferences as part of its ongoing
commitment to share relevant scientific progress and intellectual
property portfolio development.
"These recent scientific presentations serve to further expand
our contribution to improve mental and neurological health and
demonstrates PsyBio's commitment to being a leader in developing
psycho-targeted therapeutic candidates," stated Evan Levine, PsyBio's Chief Executive Officer.
"Our approach towards collaborative research remains a critical
part of our goal."
These sixteen abstracts cover a wide variety of topics
including: biosynthetic pathway and transcriptional methodologic
development; evaluation; screening and optimization of systems and
organisms; increasing bioproduction yields of natural and
non-natural products, as well as the evaluation of impulsivity,
motivational, psychiatric, and psychoactive effects of PsyBio's
portfolio of compounds.
"PsyBio remains committed to advancing scientific knowledge and
dissemination of results while ensuring intellectual property
protection," stated Michael
Spigarelli, MD, PhD, MBA, PsyBio's Chief Medical Officer.
"We are proud of the joint efforts between PsyBio and our sponsored
research collaborators that made the sixteen presentations from
process development, through biosynthesis and to neurobehavioral
testing possible. We will continue to collect data and advance the
clinical and scientific knowledge base to be able to help improve
mental and neurological health."
About PsyBio Therapeutics Corp.
PsyBio is an intellectual property driven biotechnology company
focusing on discovering and developing new, bespoke,
psycho-targeted therapeutics to potentially improve mental and
neurological health. The team has extensive experience in drug
discovery based on synthetic biology and metabolic engineering as
well as clinical and regulatory expertise progressing drugs through
human studies and regulatory protocols. Research and development is
currently ongoing for naturally occurring psychoactive tryptamines
originally discovered in different varieties of hallucinogenic
mushrooms, other tryptamines and phenethylamines and combinations
thereof. The Company utilizes a bio-medicinal chemistry approach to
therapeutic development, in which psychoactive compounds can be
utilized as a template upon which to develop precursors and
analogs, both naturally and non-naturally occurring.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that constitute
"forward-looking information" ("forward-looking
information") within the meaning of applicable Canadian
securities legislation. All statements, other than statements of
historical fact, are forward-looking information and are based on
expectations, estimates and projections as at the date of this news
release. Any statement that discusses predictions, expectations,
beliefs, plans, projections, objectives, assumptions, future events
or performance (often but not always using phrases such as
"expects", or "does not expect", "is expected", "anticipates" or
"does not anticipate", "plans", "budget", "scheduled", "forecasts",
"estimates", "believes" or "intends" or variations of such words
and phrases or stating that certain actions, events or results
"may" or "could", "would", "might" or "will" be taken to occur or
be achieved) are not statements of historical fact and may be
forward-looking information. Forward looking-statements in this
press release include statements regarding: the ability of PsyBio
to develop novel formulations to potentially treat neurologic and
psychologic conditions and other disorders; the ability of PsyBio
to launch clinical trials; the ability of PsyBio to build and
protect its intellectual property portfolio of novel drug
candidates; the ability of PsyBio to move target candidates into
scaled commercial manufacturing and regulatory application; the
ability to achieve cost competitive synthesis with reduced
environmental impact over current production methods; and the
ability of PsyBio to move target candidates into scaled commercial
manufacturing and regulatory application.
In disclosing the forward-looking information contained in this
press release, the Company has made certain assumptions, including
that: PsyBio will be successful in protecting its intellectual
property; PsyBio will be successful in discovering new valuable
target molecules; PsyBio will file one or more IND Applications
with the United States Food and Drug Administration ("FDA");
PsyBio will be successful in obtaining all necessary approvals for
clinical trials; PsyBio will be successful in launching clinical
trials; the results of preclinical safety and efficacy testing will
be favourable; PsyBio's technology will be safe and effective; a
confirmed signal will be identified in PsyBio's selected
indications; and that drug development involves long lead times, is
very expensive and involves many variables of uncertainty. Although
the Company believes that the expectations reflected in such
forward-looking information are reasonable, it can give no
assurance that the expectations of any forward-looking information
will prove to be correct. Known and unknown risks, uncertainties,
and other factors which may cause the actual results and future
events to differ materially from those expressed or implied by such
forward-looking information. Such factors include, but are not
limited to: compliance with extensive government regulations;
domestic and foreign laws and regulations adversely affecting
PsyBio's business and results of operations; decreases in the
prevailing process for psilocybin and nutraceutical products in the
markets in which PsyBio operates; the impact of COVID-19; and
general business, economic, competitive, political and social
uncertainties. Accordingly, readers should not place undue reliance
on the forward-looking information contained in this press release.
Except as required by law, the Company disclaims any intention and
assumes no obligation to update or revise any forward-looking
information to reflect actual results, whether as a result of new
information, future events, changes in assumptions, changes in
factors affecting such forward-looking information or
otherwise.
PsyBio makes no medical, treatment or health benefit claims
about PsyBio's proposed products. The FDA or other similar
regulatory authorities have not evaluated claims regarding
psilocybin and other next generation psychoactive compounds. The
efficacy of such products has not been confirmed by FDA-approved
research. There is no assurance that the use of psilocybin and
other psychoactive compounds can diagnose, treat, cure, or prevent
any disease or condition. Vigorous scientific research and clinical
trials are needed. PsyBio has not conducted clinical trials for the
use of its intellectual property. Any references to quality,
consistency, efficacy and safety of potential products do not imply
that PsyBio verified such in clinical trials or that PsyBio will
complete such trials. If PsyBio cannot obtain the approvals or
research necessary to commercialize its business, it may have a
material adverse effect on the PsyBio's performance and
operations.
The TSX Venture Exchange (the "TSXV")
has neither approved nor disapproved the contents of this news
release. Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this
release.
SOURCE PsyBio Therapeutics Corp.